Clinical Trials in Washington

Showing 6621-6640 of 9,462 trials

IV Iron for the Anemia of Traumatic Critical Illness

NCT01180894

The purpose of this clinical trial is to determine whether intravenous iron supplementation of anemic, critically ill trauma patients improves anemia and reduces the need for a red blood cell transfusion.

TraumaICU Anemia

Denver Health and Hospital Authority150 participantsStarted Jun 2011

Baltimore, Maryland, United States • Ann Arbor, Michigan, United States • New York, New York, United States +3 more locations

COMPLETEDPhase 342 miles

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006

The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).

Non-Hodgkin's LymphomaMantle Cell Lymphoma

Teva Branded Pharmaceutical Products R&D, Inc.447 participantsStarted Apr 2009

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Corona, California, United States +125 more locations

IV Iron for the Anemia of Traumatic Critical Illness

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Find Trials by Condition in Washington

Lesinurad and Febuxostat Combination Extension Study in Gout

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Asthma Exacerbation Study

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

NOLAN: Naproxen or Loratadine and Neulasta

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD